Not Yet RecruitingNot Applicable

Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery

South Korea70 participantsStarted 2024-10-28

Plain-language summary

The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent Exclusion Criteria: * preoperative renal failure requiring reran replacement therapy * preoperative liver disease * preoperative low cardiac output (EF \< 50%) * Preoperative IABP application, Atrial fibrillation, Pacemaker * contraindication for applying TEE * intraoperative withdrawal

What they're measuring

Maximal clot firmness of EXTEM

Timeframe: 10 min after completion of acute normovolemic hemodilution (ANH)

Trial details

NCT IDNCT06664320

SponsorKonkuk University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-30

Contact for this trial

Tae-Yop Kim, MD, PhD

+82-2-2030-5445 taeyop@gmail.com

View on ClinicalTrials.gov More Mitral Regurgitation trials